Zhi Tong Cai Jing·2025-06-03 08:13Group 1 - Sanofi announced a plan to acquire Blueprint Medicines for $9.1 billion, aiming to integrate Blueprint's rare disease and immunology pipeline assets to fill the profit gap after the patent expiration of Dupixent in 2031/32 [1][2] - The acquisition will be conducted at a cash price of $129 per share, representing a 27% premium over the closing price on May 30, with potential additional payments based on the success of Blueprint's drug BLU-808 [1][2] - Goldman Sachs maintains a "neutral" rating on Sanofi with a target price of €117 (ADR $67) following the announcement of the acquisition [1] Group 2 - Key assets in the acquisition include the approved tyrosine kinase inhibitor Ayvakit and the investigational drug BLU-808, which targets non-mutant KIT for chronic urticaria and allergic asthma [2] - Ayvakit is projected to reach peak sales of €2.35 billion by 2033 with a gross margin of 95%, while BLU-808 is expected to achieve peak sales of $2.7 billion (€1.7 billion) by 2033 [2] - The acquisition is expected to strengthen Sanofi's position in the rare disease sector and support its immunology pipeline, serving as a long-term alternative to Dupixent [2]